
Upfront Disease Modification: How Winrevair's HYPERION Label Update Rewrites Pulmonary Vascular Care
Dr. Dereck Mush, MD, MBAMerck & Co., Inc. is known as MSD outside the United States and Canada.
Its businesses span Pharmaceuticals, Vaccines and Animal Health.
Merck & Co. is an American multinational pharmaceutical company based in Rahway, New Jersey. Outside the United States and Canada it operates as Merck Sharp & Dohme, or MSD. It develops and sells prescription medicines and vaccines, including a large oncology franchise built around Keytruda, as well as vaccines and animal health products.
Leadership as of 14 Nov 2026.
Chairman and Chief Executive Officer
Historical co-founder
Historical co-founder
Merck & Co. is separate from Germany's Merck KGaA, whose history traces to 1668.
How Merck got here, step by step.
1891
Established on 1 January 1891 by George Merck, then 23, to distribute fine chemicals.
1933
Opened its first research laboratory, in Rahway, New Jersey.
1953
Combined with Sharp & Dohme, creating Merck Sharp & Dohme (MSD).
1963
Launched the first measles vaccine, developed under Dr. Maurice Hilleman.
1987
Introduced the first commercial FDA-approved statin and committed to donate Mectizan "as much as needed for as long as needed" to help eliminate river blindness.
1996
Received FDA approval for an HIV medicine in a record 42 days, helping pave the way for combination therapy.
2006
FDA approved its vaccine against cervical cancer caused by certain HPV types, and it launched the first DPP-4 inhibitor for type 2 diabetes.
2009
Completed its merger with Schering-Plough.
2014
FDA approved the first anti-PD-1 therapy, Merck's immuno-oncology medicine.
2021
Completed the spinoff of Organon & Co. as an independent public company on 3 June 2021.
2024
FDA approved WINREVAIR (sotatercept-csrk) for adults with pulmonary arterial hypertension on 26 March 2024.
2025
Completed the acquisition of Verona Pharma for about $10 billion on 7 October 2025, adding OHTUVAYRE for COPD.
Cancer, cardiovascular diseases, metabolic diseases, infectious diseases, neurosciences, immunology, ophthalmology, respiratory diseases and vaccines.
2025 Form 10-K.
Product snapshot, 29 Oct 2026.
Reported 29 Oct 2026.
13 Nov 2026
Positive EU CHMP opinion to expand ENFLONSIA to children up to 24 months at increased risk through their second RSV season13 Nov 2026
Positive EU CHMP opinion for WELIREG plus lenvatinib in advanced clear cell renal cell carcinoma after anti-PD-1/PD-L1 therapy9 Nov 2026
Positive Phase 2b efinopegdutide results in MASH with stage 2 to 3 fibrosis, presented at The Liver Meeting and published in The Lancet3 Nov 2026
ENHANCE-3 Phase 3 study begins, evaluating OHTUVAYRE for preventing COPD exacerbations29 Oct 2026
Third-quarter financial results and pipeline milestones
Dr. Dereck Mush, MD, MBAWINREVAIR: HYPERION and pulmonary arterial hypertension

Dr. Dereck Mush, MD, MBAPneumococcal vaccines: VAX-31 and CAPVAXIVE

Dr. Dereck Mush, MD, MBAOncology evidence: Tecentriq and the Keytruda comparator

Newsletter
The WINREVAIR briefing

Newsletter
The Variational AI collaboration briefing
Newsletter
The Merck and Moderna vaccine briefing
Related companies
Your daily HealthTech Signal
Get the latest HealthTech news, understand why it matters, and see where the industry is headed.



Read by teams at companies like: